Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases

World Journal of Surgical Oncology

Xing-Ya Li¹  Shu-Jing Shen¹  Si-Yuan Huang¹ 

[1] Department of Medicine Oncology, The First Affiliated Hospital of Zhengzhou University, 450052 No.1 of Jianshe east Road, Zhengzhou, China

关键词: Prognosis;    Treatment;    Cathological characteristics;    Clinical characteristics;    Pulmonary sarcomatoid carcinoma;   

Others  :  821532
DOI  :  10.1186/1477-7819-11-252

 received in 2013-03-28, accepted in 2013-09-22,  发布年份 2013

【 摘 要 】

Background

Pulmonary sarcomatoid carcinoma is a diagnostically challenging group of tumors. It’s a rare histologic subtype of non-small cell lung cancer.There are five subgroups of pulmonary sarcomatoid carcinoma, they are identified as pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma. We explored the clinicopathologic features and prognostic factors of this tumor.

Methods

We analyzed retrospectively the clinicopathological data of 51 patients with pulmonary sarcomatoid carcinoma who were treated in the First Affiliated Hospital of Zhengzhou University, Henan Cancer Hospital and Henan People Hospital from January 2005 to December 2012. The correlation between prognosis and age, sex, smoking history, tumor size, TNM staging, and treatment modality was analyzed by the statistical software SPSS 17.0. The survival analysis was conducted using the Kaplan-Meier method. The factors influencing survival were analyzed using univariate (Log-rank) and multivariate (Cox) models.

Results

The overall survival rates at 1, 2, 3 and 5 years were 45.5%, 35.8%, 28.2% and 20.1%, respectively. Cox univariate analyses revealed that age, tumor size, T stage, M stage, surgery or not, and postoperative chemotherapy or not, were prognostic factors. Cox multivariate analysis found that tumor size and M stage were independent prognostic factors for PSC.

Conclusions

Due to its rarity and the lack of large-scale clinical trial evidence, few studies about PSC have been reported, its clinical and pathological characteristics remain unclear, and its preoperative diagnosis and investigation of novel treatment approaches are imperative. In our study, the main factors affecting the prognosis of tumor size and M staging are the crucial prognostic factors for PSC. Surgical resection and postoperative adjuvant chemotherapy might result in better prognosis.

【 授权许可】

   
2013 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Park JS, Lee Y, Han J, Kim HK, Choi YS, Kim J, Shim YM, Kim K: Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the Lung. Oncology 2011, 81:206-213.
• [2]Pelosi G, Sonzogni A, De Pas T, Galetta D, Veronesi G, Spaggiari L, Manzotti M, Fumagalli C, Bresaola E, Nappi O, Viale G, Rosai J: Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010, 18:103-120.
• [3]Beasley MB, Brambilla E, Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005, 40:90-97.
• [4]Franks TJ, Galvin JR: Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis. Arch Pathol Lab Med 2010, 134:49-54.
• [5]Nakajima M, Kasai T, Hashimoto H, Iwata Y, Manabe H: Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer 1999, 86:608-616.
• [6]Pelosi G, Fraggetta F, Nappi O, Pastorino U, Maisonneuve P, Pasini F, Iannucci A, Solli P, Musavinasab HS, De Manzoni G, Terzi A, Viale G: Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 2003, 27:1203-1215.
• [7]Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
• [8]Koss MN, Hochholzer L, Frommelt RA: Carcinosarcomas of the lung: a clinicopathologic study of 66 patients. Am J Surg Pathol 1999, 23:1514-1526.
• [9]Chang YL, Lee YC, Shih JY, Wu CT: Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer 2001, 34:91-97.
• [10]Mochizuki T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mizuno T, Yokose T, Suzuki K, Ochiai A: Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases. Am J Surg Pathol 2008, 32:1727-1735.
• [11]Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC: Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg 2007, 84:973-980.
• [12]Venissac N, Pop D, Lassalle S, Berthier F, Hofman P, Mouroux J: Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease? J Thorac Cardiovasc Surg 2007, 134:619-623.
• [13]Rossi G, Cavazza A, Sturm N, Migaldi M, Facciolongo N, Longo L, Maiorana A, Brambilla E: Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 2003, 27:311-324.
• [14]Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H, Nishimura M, Hokkaido Lung Cancer Clinical Study Group: Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer 2010, 68:204-210.
• [15]Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Kondo H, Nakajima T, Yamamoto N: Biologic correlates of (1) F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Lung Cancer 2011, 71:144-150.
• [16]Pelosi G, Melotti F, Cavazza A, Rossi G, Maisonneuve P, Graziano P, Barbareschi M, Nakatani Y, Papotti M: A modified Vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples. Anticancer Res 2012, 32:1463-1474.
• [17]Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N: Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010, 5:460-465.
• [18]Leone A, Graziano P, Gasbarra R, Paone G, Cardillo G, Mancuso A, De Marinis F, Ricciardi S, Portalone L, Pisa R: Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer 2010, 128:732-735.
• [19]Italiano A, Cortot AB, Ilie M, Martel-Planche G, Fabas T, Pop D, Mouroux J, Hofman V, Hofman P, Pedeutour F: EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009, 125:2479-2482.
• [20]Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II: Immunohistochemical over expression of platelet-derived growth factor receptor–beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid Non–small-cell lung cancer. Clin Lung Cancer 2011, 12:369-374.